Search results for: IgE, Human Myeloma Plasma
#28626947 // Save this To Up
Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.This phase 4, single-arm, non-randomized, open-label, post approval commitment study evaluated the pharmacokinetics and safety of bortezomib in Taiwanese patients with multiple myeloma. Patients (≥20 years) with measurable secretory multiple myeloma (serum monoclonal IgG ≥10, IgA/IgE ≥5, IgD ≥0.5 g/L, IgM present [regardless of level], and urine M protein of ≥200 mg/24 h) received intravenous bortezomib 1.3 mg/m, twice weekly for 2 weeks, followed by a 10-day resting phase (days 12 to 21). Pharmacokinetics and safety were assessed at pre-specified time points. All enrolled patients (n = 18, men: 11; women: 7) completed the study. Mean (SD) C(maximum observed plasma concentration) on day 11 was 266 (77.5) ng/mL, approximately 60% higher compared with non-Asian patients receiving a similar bortezomib regimen but with overlapping ranges. Because of the protracted terminal phase, half-life (t), area under the plasma concentration-time curve from time 0 to infinity (AUC), volume of distribution (V), and systemic clearance were not assessable. All patients experienced treatment-emergent adverse events (TEAEs); 78% were drug-related. Most commonly reported TEAEs were thrombocytopenia (n = 11 [61%]), neutropenia (n = 9 [50%]), leukopenia (n = 6 [33%]), and diarrhoea (n = 6 [33%]); the most common serious adverse event was pneumonia (n = 2 [11%]). One patient had a dose reduction due to a TEAE of thrombocytopenia. Overall, bortezomib exposure (AUC) in Taiwanese patients (AUC[SD]: 230  ng·h/mL) with twice weekly intravenous administration was comparable with non-Asian population (AUC[SD]: 241  ng·h/mL). Bortezomib treatment was associated with manageable toxicity profile and did not limit the continuity of therapy.
2968 related Products with: Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.Bortezomib (PS-341) Mecha AEE-788 Mechanisms: Multi Inflammation (Human) Quan Inflammation (Human) Quan Inflammation (Human) Quan Inflammation (Mouse) Quan Inflammation (Rat) Quanti Multiple organs tumor and Multiple organ cancer tis Multiple organ cancer and Multiple organ tumor and Multiple myeloma tissue m
#25969367 // Save this To Up
IgE and risk of cancer in 37 747 individuals from the general population.Immunoglobulin E (IgE) is produced by plasma cells, often as part of an allergic immune response. It is currently unknown whether plasma IgE levels are associated with risk of cancer in individuals from the general population. We tested the hypothesis that high levels of plasma total IgE are associated with overall risk of cancer and with risk of specific cancers.
1730 related Products with: IgE and risk of cancer in 37 747 individuals from the general population.LDK-378 Mechanisms: ALK i D,L-7-Aza-3-indolylglycin Cancer Apoptosis Phospho- Top five cancer tissue ar Multiple organ cancer tis Lung cancer tissue array, Lung cancer tissue array Colon cancer and normal t Colon cancer and normal t Colon cancer, metastasize Colon cancer and matched Colon cancer tissue array
#25555008 // Save this To Up
[IgE myeloma. Laboratory typing difficulties].The IgE multiple myeloma is a rare neoplasm of plasma cell accounting for 0.01% of all plasma cell dyscrasias. They are generally of more aggressive development and to date there are no more than 50 cases published in current literature. Laboratory studies are, in these cases, essential for the classification of the monoclonal component in serum and urine. The aim of this presentation is to report a patient diagnosed with IgE myeloma and to point out that the laboratory difficulties noted in these rare cases can lead to an erroneous report.
Anti C Reactive Protein A Multiple myeloma tissue m Laboratory supplies and f Myeloma, lymphoma and nor Native Mouse Myeloma IgM Lymphoma, multiple myelom Lymphoma, myeloma and lym Multiple myeloma test tis Myeloma tissue array with
#24925397 // Save this To Up
Mast cell research.The role of mast cells in allergy remained unrevealed until the observation that they contained histamine in 1953, and then the discovery of immunoglobulin E (IgE) in 1966, nearly a century after Ehrlich's first publication. After the discovery of IgE, myeloma-derived IgE from Peter Shackford, who made a great contribution to mankind by providing 40 liters of plasma in the year prior to his death, was distributed to many researchers. This accelerated the exploration of the mechanisms involved in allergic reactions, especially regarding the role of mast cells in IgE-mediated reactions. The identification of mast cells as a progeny of a bone marrow hematopoietic stem cell in 1977 led us to the successful in vitro culture of mast cells. Along with the development of molecular biological techniques, the structure of the high-affinity IgE receptor (FcεRI) was determined in 1989. Thus, we now understand the whole molecules the expression of which is changed when mast cells are activated via FcεRI cross-linking. However, the physiological and pathological roles of mast cells, especially where IgE is not involved, are not yet fully understood. It will be necessary to determine the mechanisms involved in the 'non-IgE-mediated' steps of mast cell activation in allergic or other diseases.
Eosinophil - Mast Cell S Rat Mast Cell Chymase ELI Mouse Anti-Human Mast Cel Mouse Anti-Human Mast Cel Astra Blue 6GLL, Stain fo Cellufine Formyl , 50 ml Cellufine Formyl Media Cellufine Formyl , 500 ml Cellufine Amino , 50 ml Cellufine Amino Media Cellufine Amino , 500 ml Cellufine Amino Media
#24723328 // Save this To Up
Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients.Quantitative MS assays for Igs are compared with existing clinical methods in samples from patients with plasma cell dyscrasias, for example, multiple myeloma (MM).
1148 related Products with: Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients.Multiple myeloma tissue m Multiple lung carcinoma ( Ofloxacin CAS Number [824 Lymphoma, multiple myelom Multiple myeloma test tis Cellufine Formyl , 50 ml Cellufine Formyl Media Cellufine Formyl , 500 ml Cellufine Formyl Media Cellufine Formyl Media Formalin Solution (20%) Formalin Solution (20%)
#24369932 // Save this To Up
A murine monoclonal antibody with broad specificity for occupationally relevant diisocyanates.Diisocyanates (dNCOs) used in industrial applications are well known low molecular weight allergens. Occupational exposure is associated with adverse health outcomes including allergic sensitization and occupational asthma. In this study, we report the production and initial characterization of a dNCO-hapten specific murine IgM monoclonal antibody (mAb). Female BALB/c mice were immunized intraperitoneally with 25 μg of 4,4'-methylene diphenyl diisocyanate (MDI)-keyhole limpet hemocyanin. Following six biweekly booster immunizations, splenocytes were recovered and fused to Sp2/0-Ag14 murine myeloma cell line for hybridoma production. Hybridomas were then screened in a solid-phase indirect enzyme-linked immunosorbent assay (ELISA) against 40:1 4,4'-MDI- human serum albumin (HSA). mAb reactivity to dNCO-HSA conjugates and dNCO-HSA spiked human serum were characterized using a sandwich ELISA. One hybridoma produced a multimeric IgM mAb (15D4) that reacted with 4,4'-MDI-HSA. Sandwich ELISA analysis demonstrated comparable reactivity with other occupationally relevant dNCO-HSA adducts, including 2,4-toluene diisocyanate (TDI)-HSA, 2,6-TDI-HSA, and 1,6-hexamethylene diisocyanate (HDI)-HSA, but not other electrophilic chemical HSA conjugates. The limit of quantification (LOQ) of 4,4'-MDI-HSA, 2,4-TDI-HSA, 2,6-TDI-HSA, and 1,6-HDI-HSA sandwich ELISAs were 567.2, 172.7, 184.2, and 403.5 ng/mL (8.67, 2.60, 2.77, and 6.07 pmol/mL), respectively. In contrast, experiments using dNCO-supplemented human sera showed an increase in the detectable limit of the assay. A mAb has been produced that has potential utility for detecting mixed diisocyanate exposures in occupational environments. The mAb may have additional utility in the standardization of specific IgE detection immunoassays as well as chromatographic-mass spectrometric methods to enrich dNCO adducted HSA in the plasma of occupationally exposed workers.
2761 related Products with: A murine monoclonal antibody with broad specificity for occupationally relevant diisocyanates.MOUSE ANTI BOVINE ROTAVIR MOUSE ANTI BORRELIA BURGD MOUSE ANTI CANINE DISTEMP MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI HUMAN CD19 RPE MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI APAAP COMPLEX, RABBIT ANTI GSK3 BETA (pS Anti-Broad (Z1) Monoclona Anti-Broad (core) Monoclo Anti C Reactive Protein A Anti AGO2 Human, Monoclon
#24133829 // Save this To Up
Unusual myelomas: a review of IgD and IgE variants.Immunoglobulin D multiple myeloma (IgD MM) accounts for almost 2% of all myeloma cases. It is associated with an increased frequency of undetectable or small monoclonal (M)-protein levels on electrophoresis; osteolytic lesions; extramedullary involvement; amyloidosis; a lambda (lambda) light chain predilection; renal failure; hypercalcemia; and, often, advanced disease at diagnosis. Immunoglobulin E (IgE) MM is rare, with fewer than 50 cases reported in the literature. IgE MM presents with features similar to those of IgD MM, along with a higher incidence of plasma cell leukemia. The hallmark of IgE MM is t(11;14) (q13;q32). IgD and IgE levels are generally very low and hence may escape detection; thus, it is important that, when myeloma is suspected, patients be screened for the presence of IgD and IgE if they have an apparently free monoclonal immunoglobulin light chain in the serum. Although survival of patients with IgD MM or IgE MM is shorter in comparison to those with immunoglobulin G (IgG) MM or immunoglobulin A (IgA) MM, the outcome for patients with IgD and IgE subtypes is improving with the use of novel agents and autologous transplantation.
Human IgE antibody, Monoc Mouse anti Human IgE anti Mouse anti Human IgE anti Mouse anti Human IgE anti Mouse anti Human IgE anti Mouse anti Canine IgE ant Mouse anti Canine IgE ant Mouse anti Canine IgE ant Mouse anti Canine IgE ant Androgen Receptor (Phosph Androgen Receptor (Phosph Goat Anti-Human IgD
#24055037 // Save this To Up
Syntaxin-4 is essential for IgE secretion by plasma cells.The humoral immune system provides a crucial first defense against the invasion of microbial pathogens via the secretion of antigen specific immunoglobulins (Ig). The secretion of Ig is carried out by terminally differentiated B-lymphocytes called plasma cells. Despite the key role of plasma cells in the immune response, the mechanisms by which they constitutively traffic large volumes of Ig out of the cell is poorly understood. The involvement of Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins in the regulation of protein trafficking from cells has been well documented. Syntaxin-4, a member of the Qa SNARE syntaxin family has been implicated in fusion events at the plasma membrane in a number of cells in the immune system. In this work we show that knock-down of syntaxin-4 in the multiple myeloma U266 human plasma cell line results in a loss of IgE secretion and accumulation of IgE within the cells. Furthermore, we show that IgE co-localises with syntaxin-4 in U266 plasma cells suggesting direct involvement in secretion at the plasma membrane. This study demonstrates that syntaxin-4 plays a critical role in the secretion of IgE from plasma cells and sheds some light on the mechanisms by which these cells constitutively traffic vesicles to the surface for secretion. An understanding of this machinery may be beneficial in identifying potential therapeutic targets in multiple myeloma and autoimmune disease where over-production of Ig leads to severe pathology in patients.
(3R,4S,5R,6S)-1-Aza-4-hyd Anti C Reactive Protein A MOUSE ANTI BOVINE ROTAVIR Human IgE antibody, Monoc Mouse anti Human IgE anti Mouse anti Human IgE anti Mouse anti Human IgE anti Mouse anti Human IgE anti Mouse anti Canine IgE ant Mouse anti Canine IgE ant Mouse anti Canine IgE ant Mouse anti Canine IgE ant
#23954772 // Save this To Up
A case of IgD myeloma representing a missed biclonal paraproteinemia or isotype switch in a patient previously diagnosed with IgA-lambda myeloma.Multiple myeloma is a clonal plasma cell neoplasm that is identified in the laboratory by a presence of a monoclonal immunoglobulin or increased plasma light chain levels.
2648 related Products with: A case of IgD myeloma representing a missed biclonal paraproteinemia or isotype switch in a patient previously diagnosed with IgA-lambda myeloma.Multi organ carcinoma tis Multi organ carcinoma tis Pancreatic carcinoma and Multiple organs tumor and Multiple organ cancer tis Multiple organ cancer and Multiple organ tumor and Colorectal organ carcinom Multiple organ cancer and Multiple organ tumor tiss Multiple organ tumor tiss Multiple organ tumor tiss
#23872298 // Save this To Up
An IgE multiple myeloma: contradictory findings in clinical laboratory testing.IgE multiple myeloma is a rare kind of plasma cell disorder, characterized by an aggressive clinical course, where laboratory testing plays a fundamental role for the correct diagnosis in order to start a targeted therapy. In the present paper it is described a case of IgE myeloma where contradictory findings between immunometric and separative techniques were found.
1578 related Products with: An IgE multiple myeloma: contradictory findings in clinical laboratory testing.Multiple organ tumor tiss Multiple organ cancer tis Multiple organ tumor and Multiple organ tumor tiss Frozen multiple human org Multiple head and neck ca Multiple organ tumor with Multiple organ tumor tiss Multiple malignant melano Inflammation (Human) Quan Inflammation (Human) Quan Inflammation (Human) Quan
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia